Compare · ARGX vs TWST
ARGX vs TWST
Side-by-side comparison of argenx SE (ARGX) and Twist Bioscience Corporation (TWST): market cap, price performance, sector, and recent activity on the wire.
Summary
- Both ARGX and TWST operate in Biotechnology: Biological Products (No Diagnostic Substances) (Health Care), so they compete in similar markets.
- ARGX is the larger of the two at $55.32B, about 12.8x TWST ($4.31B).
- Over the past year, ARGX is up 52.8% and TWST is up 107.1% - TWST leads by 54.3 points.
- TWST has been more active in the news (14 items in the past 4 weeks vs 5 for ARGX).
- ARGX has more recent analyst coverage (25 ratings vs 13 for TWST).
- Company
- argenx SE
- Twist Bioscience Corporation
- Price
- $891.80+5.79%
- $69.11-6.53%
- Market cap
- $55.32B
- $4.31B
- 1M return
- +10.56%
- +16.08%
- 1Y return
- +52.81%
- +107.09%
- Industry
- Biotechnology: Biological Products (No Diagnostic Substances)
- Biotechnology: Biological Products (No Diagnostic Substances)
- Exchange
- NASDAQ
- NASDAQ
- IPO
- 2017
- 2018
- News (4w)
- 5
- 14
- Recent ratings
- 25
- 13
argenx SE
argenx SE, a clinical-stage biotechnology company, focuses on developing antibody-based therapies for the treatment of autoimmune diseases, hematology, and cancer. It is developing its lead product candidate, efgartigimod, for the treatment of patients with myasthenia gravis; immune thrombocytopenia in Phase III; pemphigus vulgaris in Phase III; chronic inflammatory demyelinating polyneuropathy in Phase III; and ENHANZE SC in pre-clinical stages. The company is also developing cusatuzumab in Phase II clinical stage in hematological cancer indications; ARGX-117 in phase I clinical trial with therapeutic potential in both orphan and large autoimmune inflammatory diseases; and preclinical products, including ARGX-118 for airway inflammation. Its partnered product candidates include ARGX-112 for treating skin inflammation, ARGX-116 for the treatment of dyslipidemia, and ARGX-115 for cancer immunotherapy, which are in Phase I clinical stages; and ARGX-114 for treating fibrosisand ARGX-119 for treating neuromuscular indications, which are in preclinical stage. The company has strategic partnership with AbbVie S.Ã.R.L. and LEO Pharma A/S; and collaboration agreement with Cilag GmbH International, Staten Biotechnology B.V., and Shire International GmbH. argenx SE was incorporated in 2008 and is based in Breda, the Netherlands.
Twist Bioscience Corporation
Twist Bioscience Corporation, a synthetic biology company, manufactures and sells synthetic DNA-based products. The company's DNA synthesis platform enables the manufacturing of synthetic DNA by writing DNA on a silicon chip. It offers synthetic DNA-based products, including synthetic genes, tools for sample preparation, antibody libraries for drug discovery and development, and DNA as a digital data storage medium. The company has collaboration agreements with ImmunoPrecise Antibodies Ltd.; Victorian Clinical Genetic Services; Vivlion GmbH; and Kyowa Kirin Pharmaceutical Research, Inc. Twist Bioscience Corporation was founded in 2013 and is headquartered in South San Francisco, California.
Latest ARGX
- SEC Form 6-K filed by argenx SE
- argenx Presents New Efgartigimod Data Showing Long-Term Sustained Patient Benefit in Myositis and Sjogren's Disease at EULAR 2026
- argenx to Host Myositis R&D Webinar on June 23, 2026
- argenx to Present at Upcoming Investor Conferences
- The Biology Came First.
- SEC Form 6-K filed by argenx SE
- argenx Announces U.S. FDA Approval Expanding VYVGART and VYVGART Hytrulo for Use in All Adult Patients Living with gMG
- SEC Form 6-K filed by argenx SE
- argenx Reports First Quarter 2026 Financial Results and Provides Business Update
- argenx to Present at BofA Securities 2026 Health Care Conference
Latest TWST
- Chief Financial Officer Laponis Adam sold $280,000 worth of shares (4,000 units at $70.00) as part of a pre-agreed trading plan, decreasing direct ownership by 3% to 112,675 units (SEC Form 4)
- Officer Cho Dennis sold $990,799 worth of shares (14,205 units at $69.75) as part of a pre-agreed trading plan, decreasing direct ownership by 11% to 120,094 units (SEC Form 4)
- Director Starovasnik Melissa A. sold $170,000 worth of shares (2,500 units at $68.00) as part of a pre-agreed trading plan, decreasing direct ownership by 10% to 22,222 units (SEC Form 4)
- Chief Executive Officer Leproust Emily M. exercised 16,470 shares at a strike of $8.82 and sold $1,118,555 worth of shares (16,470 units at $67.91) as part of a pre-agreed trading plan (SEC Form 4)
- Chief Accounting Officer Werner Robert F. sold $49,987 worth of shares (800 units at $62.48), decreasing direct ownership by 2% to 48,186 units (SEC Form 4) (tax liability)
- Chief Executive Officer Leproust Emily M. exercised 49,299 shares at a strike of $8.82 and sold $3,213,653 worth of shares (49,299 units at $65.19) as part of a pre-agreed trading plan (SEC Form 4)
- Director Starovasnik Melissa A. sold $30,520 worth of shares (500 units at $61.04) as part of a pre-agreed trading plan, decreasing direct ownership by 2% to 24,722 units (SEC Form 4)
- Twist Bioscience to Present at William Blair 46th Annual Growth Stock Conference
- SVP of Human Resources Green Paula sold $74,507 worth of shares (1,399 units at $53.26), decreasing direct ownership by 1% to 121,589 units (SEC Form 4) (for tax liability)
- President and COO Finn Patrick John sold $221,549 worth of shares (4,160 units at $53.26), decreasing direct ownership by 1% to 274,804 units (SEC Form 4) (withholding obligation)